## Philippe Seksik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8902920/publications.pdf

Version: 2024-02-01

		26567	11581
147	19,204	56	135
papers	citations	h-index	g-index
155	155	155	20387
155	155	155	20307
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	<i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16731-16736.	3.3	3,581
2	Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology, 2011, 140, 1785-1794.e4.	0.6	1,718
3	Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Diseases, 2009, 15, 1183-1189.	0.9	1,052
4	CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nature Medicine, 2016, 22, 598-605.	15.2	1,001
5	Fungal microbiota dysbiosis in IBD. Gut, 2017, 66, 1039-1048.	6.1	939
6	Predictors of Crohn's Disease. Gastroenterology, 2006, 130, 650-656.	0.6	795
7	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut, 2013, 62, 531-539.	6.1	663
8	Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut, 2003, 52, 237-242.	6.1	612
9	Identification of an anti-inflammatory protein from <i>Faecalibacterium prausnitzii</i> , a commensal bacterium deficient in Crohn's disease. Gut, 2016, 65, 415-425.	6.1	585
10	Specificities of the fecal microbiota in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 106-111.	0.9	373
11	Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut, 2006, 55, 842-847.	6.1	351
12	Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease. Gastroenterology, 2013, 145, 166-175.e8.	0.6	311
13	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases, 2019, 78, 209-217.	0.5	273
14	Natural history of Crohn's disease. Inflammatory Bowel Diseases, 2010, 16, 953-961.	0.9	228
15	Biodiversity of the Mucosa-Associated Microbiota Is Stable Along the Distal Digestive Tract in Healthy Individuals and Patients With Ibd. Inflammatory Bowel Diseases, 2005, 11, 473-480.	0.9	220
16	Increase in fecal primary bile acids and dysbiosis in patients with diarrheaâ€predominant irritable bowel syndrome. Neurogastroenterology and Motility, 2012, 24, 513.	1.6	209
17	Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome, 2020, 8, 12.	4.9	203
18	Analysis of bacterial bowel communities of IBD patients: What has it revealed?. Inflammatory Bowel Diseases, 2008, 14, 858-867.	0.9	193

#	Article	IF	Citations
19	Olmesartan-associated enteropathy: results of a national survey. Alimentary Pharmacology and Therapeutics, 2014, 40, 1103-1109.	1.9	166
20	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut, 2011, 60, 198-203.	6.1	160
21	Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn $\hat{E}^1\!\!/\!\!4$ s Disease. Inflammatory Bowel Diseases, 2014, 20, 1.	0.9	160
22	Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut, 2007, 56, 1404-1409.	6.1	157
23	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut, 2010, 59, 1363-1368.	6.1	155
24	Significance of Erythema Nodosum and Pyoderma Gangrenosum in Inflammatory Bowel Diseases. Medicine (United States), 2008, 87, 281-293.	0.4	151
25	Bile acid profiling in human biological samples: Comparison of extraction procedures and application to normal and cholestatic patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 899, 135-145.	1.2	139
26	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. American Journal of Gastroenterology, 2017, 112, 337-345.	0.2	138
27	The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Current Opinion in Gastroenterology, 2010, 26, 327-331.	1.0	133
28	Temperature Gradient Gel Electrophoresis of Fecal 16S rRNA Reveals Active Escherichia coli in the Microbiota of Patients with Ulcerative Colitis. Journal of Clinical Microbiology, 2006, 44, 3172-3177.	1.8	131
29	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	3.8	129
30	Molecular inventory of faecal microflora in patients with Crohn's disease. FEMS Microbiology Ecology, 2004, 50, 25-36.	1.3	128
31	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With UlcerativeÂColitis. Gastroenterology, 2016, 150, 380-388.e4.	0.6	114
32	Factors affecting outcomes in Crohn's disease over 15â€years. Gut, 2012, 61, 1140-1145.	6.1	108
33	Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterology and Motility, 2016, 28, 1330-1340.	1.6	103
34	Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis. American Journal of Gastroenterology, 2008, 103, 637-642.	0.2	97
35	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World Journal of Gastroenterology, 2008, 14, 3497.	1.4	87
36	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. Gut Microbes, 2018, 9, 55-60.	4.3	85

#	Article	IF	CITATIONS
37	Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?. Gut, 2018, 67, gutjnl-2016-311892.	6.1	84
38	Factors associated with pregnancy outcome in antiâ€ <scp>TNF</scp> treated women with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 40, 363-373.	1.9	82
39	Bacterial protein signals are associated with Crohn's disease. Gut, 2014, 63, 1566-1577.	6.1	80
40	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	2.4	80
41	Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterology Journal, 2020, 8, 303-313.	1.6	79
42	Search for Localized Dysbiosis in Crohn's Disease Ulcerations by Temporal Temperature Gradient Gel Electrophoresis of 16S rRNA. Journal of Clinical Microbiology, 2005, 43, 4654-4658.	1.8	76
43	Effects of light smoking consumption on the clinical course of Crohn $\hat{E}^{1}\!\!/4$ s disease. Inflammatory Bowel Diseases, 2009, 15, 734-741.	0.9	76
44	Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. Gut, 2020, 69, 462-472.	6.1	76
45	Risk Factors Associated With Small Bowel Adenocarcinoma in Crohn's Disease: A CaseControl Study. American Journal of Gastroenterology, 2008, 103, 1730-1736.	0.2	72
46	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Alimentary Pharmacology and Therapeutics, 2009, 29, 1106-1113.	1.9	72
47	Male gender, active smoking and previous intestinal resection are risk factors for postâ€operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 48, 924-932.	1.9	71
48	Risk Factors for Neoplasia in Inflammatory Bowel Disease Patients With Pancolitis. American Journal of Gastroenterology, 2010, 105, 2405-2411.	0.2	69
49	Tolerance of Probiotics and Prebiotics. Journal of Clinical Gastroenterology, 2004, 38, S67-S69.	1.1	67
50	Video Capsule Endoscopy for Investigation of Obscure Gastrointestinal Bleeding: Feasibility, Results, and Interobserver Agreement. Endoscopy, 2005, 37, 617-621.	1.0	66
51	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genetics, 2018, 14, e1007329.	1.5	66
52	Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterologie Clinique Et Biologique, 2005, 29, 600-603.	0.9	65
53	Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID. American Journal of Gastroenterology, 2014, 109, 1443-1449.	0.2	63
54	Long-term Outcome of Patients With Crohn's Disease Who Respond to Azathioprine. Clinical Gastroenterology and Hepatology, 2013, 11, 389-394.	2.4	60

#	Article	IF	CITATIONS
55	Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy. PLoS ONE, 2015, 10, e0125024.	1.1	60
56	Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflammatory Bowel Diseases, 2011, 17, 565-572.	0.9	59
57	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 712-720.	1.9	59
58	Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study. Digestive and Liver Disease, 2017, 49, 643-646.	0.4	57
59	Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria. Inflammatory Bowel Diseases, 2007, 13, 684-692.	0.9	54
60	Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflammatory Bowel Diseases, 2009, 15, 1044-1048.	0.9	54
61	Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. Journal of Crohn's and Colitis, 2016, 10, 1179-1185.	0.6	53
62	Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation. Digestive and Liver Disease, 2016, 48, 242-247.	0.4	53
63	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 59-67.	2.4	52
64	Palmitic acid damages gut epithelium integrity and initiates inflammatory cytokine production. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158530.	1.2	49
65	Manipulation of the bacterial flora in inflammatory bowel disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 47-61.	1.0	48
66	Cellular and Physiological Effects of Probiotics and Prebiotics. Mini-Reviews in Medicinal Chemistry, 2004, 4, 889-896.	1.1	47
67	Changes in the Lémann Index Values During the First Years of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1633-1640.e3.	2.4	47
68	Complications and surgery in the inflammatory bowel diseases biological era. Current Opinion in Gastroenterology, 2014, 30, 378-384.	1.0	46
69	Impact of N-Acyl-Homoserine Lactones, Quorum Sensing Molecules, on Gut Immunity. Frontiers in Immunology, 2020, 11, 1827.	2.2	46
70	Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota. PLoS ONE, 2018, 13, e0202587.	1.1	43
71	Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 44, 1102-1113.	1.9	42
72	Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohn's Disease. Gastroenterology, 2020, 159, 2193-2202.e5.	0.6	41

#	Article	IF	Citations
73	Probiotics and health: new facts and ideas. Current Opinion in Biotechnology, 2002, 13, 486-489.	3.3	40
74	Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. Gut, 2007, 56, 152-154.	6.1	40
75	Current smoking differentially affects blood mononuclear cells from patients with crohn $\hat{E}\frac{1}{4}$ s disease and ulcerative colitis: Relevance to its adverse role in the disease. Inflammatory Bowel Diseases, 2012, 18, 1101-1111.	0.9	40
76	Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: A retrospective assessment. Digestive and Liver Disease, 2014, 46, 1086-1092.	0.4	40
77	Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease. American Journal of Gastroenterology, 2020, 115, 1084-1093.	0.2	40
78	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Molecular Nutrition and Food Research, 2008, 52, 906-912.	1.5	35
79	MD-2 controls bacterial lipopolysaccharide hyporesponsiveness in human intestinal epithelial cells. Life Sciences, 2008, 82, 519-528.	2.0	35
80	Genetic effects on the commensal microbiota in inflammatory bowel disease patients. PLoS Genetics, 2019, 15, e1008018.	1.5	35
81	T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. Gut, 2019, 68, 1961-1970.	6.1	35
82	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 930-935.	0.6	34
83	A Cell-Penetrant Manganese Superoxide Dismutase (MnSOD) Mimic Is Able To Complement MnSOD and Exerts an Antiinflammatory Effect on Cellular and Animal Models of Inflammatory Bowel Diseases. Inorganic Chemistry, 2017, 56, 2545-2555.	1.9	33
84	Fatal herpetic hepatitis in adult following short corticotherapy: a case report. Intensive Care Medicine, 1999, 25, 415-417.	3.9	32
85	Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine a in patients with steroid resistant ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 19-23.	0.9	32
86	The presence of the anti-inflammatory protein MAM, from < i > Faecalibacterium prausnitzii < /i >, in the intestinal ecosystem. Gut, 2016, 65, 882.1-882.	6.1	32
87	Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 141-149.e2.	2.4	32
88	Long-term Follow-up After Ileorectal Anastomosis for Ulcerative Colitis. Annals of Surgery, 2017, 266, 1029-1034.	2.1	30
89	Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. PLoS ONE, 2018, 13, e0201991.	1.1	29
90	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 775-778.e6.	1.5	28

#	Article	IF	CITATIONS
91	Tolerance of 4-Aminosalicylic Acid Enemas in Patients with Inflammatory Bowel Disease and 5-Aminosalicylic–induced Acute Pancreatitis. Inflammatory Bowel Diseases, 2004, 10, 258-260.	0.9	27
92	Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. European Journal of Gastroenterology and Hepatology, 2010, 22, 842-847.	0.8	27
93	Prior appendectomy and the phenotype and course of Crohn's disease. World Journal of Gastroenterology, 2006, 12, 1235.	1.4	26
94	A Double-Blind Placebo-Controlled Study of Intravenous Clodronate for Prevention of Steroid-Induced Bone Loss in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2007, 5, 1184-1189.	2.4	26
95	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1602-1610.e1.	2.4	26
96	Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. Inflammatory Bowel Diseases, 2016, 22, 1362-1369.	0.9	24
97	Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 2020, 18, 150-157.e1.	2.4	23
98	Evaluation of the compounds commonly known as superoxide dismutase and catalase mimics in cellular models. Journal of Inorganic Biochemistry, 2021, 219, 111431.	1.5	22
99	Circulating bile acids concentration is predictive of coronary artery disease in human. Scientific Reports, 2021, 11, 22661.	1.6	22
100	Role of adherent and invasive <i>Escherichia coli</i> in Crohn's disease: lessons from the postoperative recurrence model. Gut, 2023, 72, 39-48.	6.1	22
101	Noncolorectal Malignancies in Inflammatory Bowel Disease: More than Meets the Eye. Digestive Diseases, 2009, 27, 375-381.	0.8	21
102	Understanding Microbiome Data: A Primer for Clinicians. Digestive Diseases, 2015, 33, 11-16.	0.8	20
103	Postprandial bile acid levels in intestine and plasma reveal altered biliary circulation in chronic pancreatitis patients. Journal of Lipid Research, 2018, 59, 2202-2213.	2.0	20
104	Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. Gut Microbes, 2022, $14$ , .	4.3	20
105	Rotavirus-Like Particles: A Novel Nanocarrier for the Gut. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	18
106	Saccharomyces boulardii CNCM I-745 Modulates the Fecal Bile Acids Metabolism During Antimicrobial Therapy in Healthy Volunteers. Frontiers in Microbiology, 2019, 10, 336.	1.5	18
107	Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis. World Journal of Gastroenterology, 2010, 16, 583.	1.4	18
108	Gossip in the gut: Quorum sensing, a new player in the host-microbiota interactions. World Journal of Gastroenterology, 2021, 27, 7247-7270.	1.4	18

#	Article	IF	CITATIONS
109	Regulation of colon cancer cell proliferation and migration by MD-2 activity. Innate Immunity, 2011, 17, 414-422.	1.1	17
110	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. BMJ Open, 2018, 8, e021037.	0.8	17
111	Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients and Controls. Frontiers in Cellular and Infection Microbiology, 2018, 8, 336.	1.8	17
112	Anti-inflammatory activity of superoxide dismutase mimics functionalized with cell-penetrating peptides. Dalton Transactions, 2020, 49, 2323-2330.	1.6	17
113	The intestinal quorum sensing 3-oxo-C12:2 Acyl homoserine lactone limits cytokine-induced tight junction disruption. Tissue Barriers, 2020, 8, 1832877.	1.6	16
114	Intracellular location matters: rationalization of the anti-inflammatory activity of a manganese( <scp>ii</scp> ) superoxide dismutase mimic complex. Chemical Communications, 2020, 56, 7885-7888.	2.2	16
115	Longâ€ŧerm efficacy of fibrin glue injection for perianal fistulas in patients with Crohn's disease. Colorectal Disease, 2021, 23, 894-900.	0.7	15
116	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, 1269-1280.	0.6	15
117	Sera from patients with Crohnâ∈™s disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity. Innate Immunity, 2010, 16, 381-390.	1.1	13
118	Current Smoking, Not Duration of Remission, Delays Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease Relapse Following Azathioprine Withdrawal. Inflammatory Bowel Diseases, 2010, 16, 362-363.	0.9	12
119	Acute cryptosporidiosis as a cause of sudden recurrence of digestive symptoms in patients with Crohn's disease. Journal of Crohn's and Colitis, 2010, 4, 669-670.	0.6	11
120	Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID. Inflammatory Bowel Diseases, 2022, 28, 1198-1206.	0.9	11
121	Faster and less invasive tools to identify patients with ileal colonization by adherentâ€invasive ⟨i⟩E. coli⟨ i⟩ in Crohn's disease. United European Gastroenterology Journal, 2021, 9, 1007-1018.	1.6	11
122	Risk of serious infection in healthcare workers with inflammatory bowel disease: a caseâ€control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology and Therapeutics, 2018, 48, 713-722.	1.9	10
123	An easy-to-implement combinatorial approach involving an activity-based assay for the discovery of a peptidyl copper complex mimicking superoxide dismutase. Chemical Communications, 2020, 56, 399-402.	2.2	10
124	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Digestive and Liver Disease, 2022, 54, 309-315.	0.4	10
125	3-oxo-C12:2-HSL, quorum sensing molecule from human intestinal microbiota, inhibits pro-inflammatory pathways in immune cells via bitter taste receptors. Scientific Reports, 2022, 12, .	1.6	9
126	Azathioprine May Not be Associated With Development of Colorectal Tumors With Microsatellite Instability in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2016, 111, 149-151.	0.2	8

#	Article	IF	CITATIONS
127	Anti-Inflammatory Effects of Analogues of N-Acyl Homoserine Lactones on Eukaryotic Cells. International Journal of Molecular Sciences, 2020, 21, 9448.	1.8	8
128	Hidradenitis Suppurativa and Crohn's Disease. , 2006, , 50-57.		6
129	Inertness of Superoxide Dismutase Mimics Mn(II) Complexes Based on an Open-Chain Ligand, Bioactivity, and Detection in Intestinal Epithelial Cells. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-16.	1.9	6
130	Integrative Network-based Analysis of Colonic Detoxification Gene Expression in Ulcerative Colitis According to Smoking Status. Journal of Crohn's and Colitis, 2016, 11, jjw179.	0.6	5
131	Early Azathioprine in Crohnʽs Disease. Inflammatory Bowel Diseases, 2013, 19, 674-675.	0.9	4
132	Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?. Current Drug Targets, 2013, 14, 1471-1479.	1.0	4
133	Meta-Analysis of IBD Gut Samples Gene Expression Identifies Specific Markers of Ileal and Colonic Diseases. Inflammatory Bowel Diseases, 2022, 28, 775-782.	0.9	4
134	Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. Digestive and Liver Disease, 2020, 52, 1323-1330.	0.4	3
135	Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort. Journal of Crohn's and Colitis, 2022, , .	0.6	3
136	Safety of High Doses of Mesalazine During Pregnancy. American Journal of Gastroenterology, 2005, 100, 1897-1898.	0.2	2
137	Single Immunoglobulin Infusion Can Reverse Hemodynamic Failure Associated With Severe Clostridium difficile Colitis. American Journal of Gastroenterology, 2009, 104, 2649-2650.	0.2	2
138	Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes. Journal of Crohn's and Colitis, 2020, 14, 342-350.	0.6	2
139	Deciphering the Metal Speciation in Lowâ€Molecularâ€Weight Complexes by IMSâ€MS: Application to the Detection of Manganese Superoxide Dismutase Mimics in Cell Lysates. Angewandte Chemie - International Edition, 2022, 61, .	7.2	2
140	Tu1137 Hemophagocytic Syndrome During Inflammatory Bowel Disease (IBD): A Serious and Unfamiliar Complication of Immunosuppressive Therapy. Gastroenterology, 2013, 144, S-771-S-772.	0.6	1
141	Increased risk of permanent stoma in Crohnâ∈™s disease associated with hidradenitis suppurativa: a caseâ€control study. Alimentary Pharmacology and Therapeutics, 2020, 52, 303-310.	1.9	1
142	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. , $0$ , .		1
143	Microbiote et maladies inflammatoires chroniques intestinales. Revue Du Rhumatisme (Edition) Tj ETQq $1\ 1\ 0.78$	84314 rgBT 0.0	√Overlock 10
144	A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease. Hepatology, 2021, 74, 3549-3551.	3.6	0

#	Article	IF	CITATIONS
145	How to Identify High-Risk Patients in Inflammatory Bowel Disease?. , 2012, , 713-725.		0
146	Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease, 2022, 54, 1350-1357.	0.4	0
147	Deciphering the Metal Speciation in Lowâ€Molecularâ€Weight Complexes by IMSâ€MS: Application to the Detection of Manganese Superoxide Dismutase Mimics in Cell Lysates. Angewandte Chemie, 0, , .	1.6	0